This poster includes information about:
- Functional brain slice electrophysiology by HD-MEA platform
- Combined neuronal circuitry studies through functional brain tissue imaging
This poster includes information about:
Tags: Neuroscience, Posters, Hit & Target ID/Validation, In vitro Biology
Date: 07 July, 2022
Location: Babraham Research Campus, Cambridge UK
Attendees: Oksana Nikolayenko
Date: 06 July, 2022
Location: Espaces Diderot, Paris
Attendees: Alicia Rosell-Hidalgo
Presenting: Alicia Rosell-Hidalgo - Utilizing in vitro mechanistic assays in DILI risk assessment
Date: 4-5 July, 2022
Location: The Francis Crick, London, UK
Attendees: Phil Butler
Learn more about New Modalities in Drug Discovery
How to knock down proteins driving disease processes in a cell
Many diseases are caused by the overproduction of certain proteins. The traditional approach to interfere with these proteins is based on small molecules or antibodies blocking these proteins or their corresponding target, e.g., receptors. Thanks to the recent progress of nucleic acid research, there are several new approaches today which intervene at different stages, from gene regulation to transcription to translation: CRISPR-Cas9 methods to target the DNA, zinc finger repressors targeting gene transcription, or RNA-molecules (antisense oligonucleotides, RNA interference, micro RNAs, etc.) to inactivate the mRNA or to suppress the translation. All approaches come with advantages and disadvantages. The main problem with DNA- and RNA-based medicine is delivery, followed by off-target-effects.
There are, however other new knockdown strategies as well, e.g., enhancing the protein clearance pathways to speed up the degradation of unwanted proteins, such as the autophagy-lysosome pathway and the ubiquitin-proteasome system (UPS).
Transcriptomics, data analysis, and AI/ML platforms as basis for partnership with BMS in targeted protein degradation
Since 2018, the latter technology of targeted protein degradation is also being used in a cooperation with Bristol Myers Squibb (BMS) to identify first-in-class drug candidates in oncology to treat solid tumors. For this collaboration, Evotec uses its PanOmics platform, EVOpanOmics, which combines enhanced throughput proteomics, high-throughput transcriptomics, and cell imaging with the integrated data analysis platform EVOpanHunter and Evotec’s AI/ML-based drug discovery and development platforms.
This research has led to the discovery of novel first-in-class molecular glue degraders. These small, drug-like compounds induce interactions between an E3 ubiquitin ligase and a molecular target, leading to ubiquitination and subsequent degradation of the recruited protein. The resulting therapeutic effect is long-lasting as the molecular glue degraders themselves are not degraded in the process and can initiate the degradation process through several iterations. BMS is a leader in this field based in particular on its unique library of cereblon E3 ligase modulators (CELMoD®) with specific protein-binding properties. Based on the needs of this project, Evotec focused on the development of dedicated and innovative software solutions that greatly helped to accelerate not only the project’s progress but also contributed to the overall progression of Evotec’s PanHunter platform.
The approach has generated a pipeline of novel first-in-class programs, two of which have transitioned successfully into lead optimization after completing respective validation processes on Evotec’s platforms. In this context, Evotec´s integrated data analysis platform panHunter and the Company’s AI and machine learning tools are used to quickly screen, share, and validate results – not only by Evotec, but also by BMS scientists. In May 2022, the partnership was expanded even further for an additional 8 years with the goal to once again broaden and deepen the strategic alliance.
Targeted protein degradation is not only useful in oncology - a number of other diseases, e.g. Alzheimer’s, bacterial and viral infections lead to the presence of unwanted proteins inside cells that may be marked for destruction by this powerful technology. Evotec therefore is welcoming partners interested in exploring this approach in collaborations.
To learn more about the BMS collaboration and the use of targeted protein degradation technology read the official press release.
Tags: Oncology, Blog, Modelling and Simulation
Toxicokinetic evaluation is a regulatory and scientific requirement in the drug development process. To obtain plasma, blood is generally withdrawn by a conventional venous collection method. Microsampling is a less invasive sampling technique, which allows to reduce the stress correlated to the conventional blood sampling and to decrease the number of rodents for a preclinical study. The implementation of microsampling in particular, in non-human primate can reduce the stress and promote a positive interaction with technical staff which improves the overall well-being of the animal (refinement).
In this poster we summarise the work done to evaluate the possible influence of the blood sampling method on drug plasma concentrations, using LC-MS/MS methods in non-human primate for four drugs selected based on acid-base and volume of distribution properties.
The poster was presented by our expert Rossella Cardin at the 24th International Reid Bioanalytical Forum held in Cambridge, UK, on June 13-16, 2022.
Tags: Posters, ADME/DMPK, IND Enabling Studies/Preclinical Development, Toxicology & Safety
Date: 27-28 June 2022
Location: Alderly Park, Congleton Rd, Macclesfield, UK
Attendees: Steve England, Kirsty Holden
Join Evotec at the UK SPINE 2022!
Date: 22 June 2022
Location: Rome, Italy
Our Evotec company in Verona, Italy, is a sponsor at "Fare rete adesso. Per un ecosistema dinamico dell'innovazione", the first event of the 2022 edition of "Biotech, il futuro migliore.", organised by Assobiotec.
Topics will cover: coordination between different levels of government - national, regional, local -, regulatory simplification, public-private collaboration.
Program available here
Participants:
Fabrizio Greco - Assobiotec
Isabella Signori - EY
Edgardo Filippone - Siga, University of Naples Federico II
Fabio Rolfi - Lombardy Region
Elena Sgaravatti - Assobiotec
Marco Baccanti - ENEA Tech and Biomedical
Angela Ianaro - Parliamentary Intergroup #Science & #Health
Maria Rosaria Capobianchi - L. Spallanzani IRCCS
Free admission, after registration, limited places. Program and how to register here
Powered by StartupItalia
Event language is Italian.
Learn more about fully integrated development at Evotec.
Evotec is a fully-integrated drug discovery and development partner, providing a comprehensive source of high quality scientific solutions with consultant-level expertise to our partners, which includes fully integrated research and development as well as clinical development through to Proof of Concept.
Tags: Fact Sheets, Clinical Development
Date: 19-21 October 2022
Location: Evotec Campus Levi-Montalcini, Verona, Italy
Evotec will host the 2022 IBIG Forum and the two pre-forum courses at its site in Verona, Italy.
We are really happy to host this Forum in Verona after two years that the event was held remotely due to the Covid pandemic!
The Forum is organized by the Italian Biostatistics Group(IBIG), a working group of SIMeF (Società Italiana di Medicina Farmaceutica) and is the most important Italian annual meeting congress for biostatisticians, data managers and statistical programmers from the world of industry, independent research and academia.
The two parallel pre-forum (19th October) courses will be:
The Forum (20th -21st October) will be divided into two main sessions:
Evotec will contribute to the scientific program and acting as moderator as part of the group’s board with our Research Expert Clinical Biostatistician Andrea Nizzardo.
You can register to the Forum here
Registrations to the pre-forum courses can be made here
Looking forward to meeting you in Verona on 19-21 October!